Treatment of respiratory tract diseases and infections with ascorbic acid compositions
AssigneeRenovion, Inc.
InventorsDan Copeland, Carolyn Durham, Thomas E. Richardson
Life of this patent
Estimating the term…
Abstract
The application is directed to a method of inhibiting or reducing growth of clinical isolate bacteria comprising contacting the clinical isolate with a composition comprising glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof.
Claims30
A method of treating a subject suffering from or at risk for a chronic clinical isolate bacterial infection comprising administering to the subject a composition comprising (a) glutathione or a pharmaceutically-acceptable salt thereof, and (b) ascorbic acid or a pharmaceutically acceptable salt thereof, wherein the composition (i) inhibits or reduces growth of a clinical isolate bacteria or (ii) inhibits or reduces formation of a clinical isolate bacteria biofilm;
- wherein the clinical isolate bacteria is selected from the group consisting of Burkholderia cepacia, methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Moraxella catarrhalis, Stenotrophomonas maltophilia, and Acinetobacter baumannii.
Dependencies are inferred from the claim text.